ARVN today
$6.85-$0.02 (-0.26%)close Nov 13, 2026Trend
DailyUptrend (starting)
4 hourStrong Bearish
1 hourStrong Bullish
15 minBullish
5 minExpanding
Daily trend turns down below $6.74
Key levels
Resistance$8.03
Resistance$7.20
Support$6.33
Latest news & SEC filings
SEC FilingArvinas, Inc. filed an insider trading report (Form 4)
AnalystBofA Securities trims its valuation view on Arvinas to $15
ProductArvinas to share first human trial results for ARV-393 at ASH 2026
DealArvinas files $400M mixed shelf registration
All ARVN news →About Arvinas
Arvinas creates drugs that recruit a cell's normal machinery for breaking down unwanted proteins, aiming to remove targets previously considered undruggable. Its experimental treatments address breast cancer, lymphoma, KRAS-mutant tumors, and neurological conditions such as Parkinson's disease. The company collaborates with partners including Pfizer, Genentech and Novartis on research and development. It is based in the United States.
Based on the company's 10-K filed Feb 24, 2026.
Nasdaq · Healthcare
ARVINAS, INC. (ARVN)
What Is the Price Target for ARVN?
SEPT Low Target
$11.00
SEPT Mid Target
$14.00
SEPT High Target
$21.00
Analyst Consensus
$14.00
Is ARVN a Buy or Sell Right Now?
Thesis
- •Revenue growing -0.3% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ARVN.
Start Free Trial →Is ARVN Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, PEG, Analyst Consensus
Fair Value
$15.19
30
Moat Score
NONE
5/9
Piotroski Score
-1.3
Altman Z-Score
What Is Smart Money Doing with ARVN?
Insider Signal
SELLING
1 buys / 17 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Teel Randy | director officer | Sale | 2,209 | $20K | May 21, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ARVN Growth Story
Revenue YoY
-0.3%
3yr Revenue CAGR
26.0%
EPS Growth YoY
58.84%
FCF Growth YoY
-5.6%
Revenue Trend
ACCELERATING
Dark Pool Trades for ARVN
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ARVN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:24:24 | $6.85 | 3,500 | $$24K | BUY |
| 17:49:11 | $6.88 | 1,000 | $$7K | SELL |
| 17:48:02 | $6.89 | 1,400 | $$10K | SELL |
| 17:35:58 | $6.90 | 1,000 | $$7K | BUY |
| 17:32:04 | $6.88 | 1,400 | $$10K | BUY |
5 dark pool trades shown · $$57K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for ARVINAS, INC. (ARVN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (6 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ARVN — frequently asked questions
What is ARVN stock price today?
ARVINAS, INC. (ARVN) is at $6.85, down 0.26% (-$0.02) at the Nov 13, 2026 close.
Why is ARVN stock moving today?
Latest ARVN news — Nov 9, 2026: Arvinas, Inc. filed an insider trading report (Form 4) · Nov 6, 2026: BofA Securities trims its valuation view on Arvinas to $15
What is the ARVN price target?
The average analyst price target for ARVN is $14.00, ranging from $11 to $21, based on 7 analysts. Latest: HC Wainwright & Co. maintains on Nov 3, 2026.
What do analysts rate ARVN?
Analyst ratings for ARVN: 0 Buy, 7 Hold, 0 Sell — consensus Hold.
Did ARVN beat earnings?
ARVN last reported on Nov 3, 2026: EPS -$0.82 vs -$0.88 expected — a beat of 6.4%.
What is ARVN's P/E ratio?
ARVN trades at a P/E of 28.6 vs a Healthcare average of 17.8.
Does ARVN pay a dividend?
ARVN does not currently pay a dividend.
How much debt does ARVN have?
ARVINAS, INC. reported $1M of debt and $94M of cash (Jun 30, 2026).
What are ARVN support and resistance levels?
Support: $6.33. Resistance: $7.20, $8.03, $8.96.
What are insiders doing with ARVN?
Insider activity: SELLING, 1 buys and 17 sells in the last 90 days.
What is the latest news on ARVN?
Nov 9, 2026: Arvinas, Inc. filed an insider trading report (Form 4) · Nov 6, 2026: BofA Securities trims its valuation view on Arvinas to $15 · Nov 5, 2026: Arvinas to share first human trial results for ARV-393 at ASH 2026